For example, Lyxumia® (Lixisenatide), an analogue of glucagon-like peptide 1 (GLP-1) isolated from Gila monster venom, was launched by Sanofi and is a GLP-1 receptor agonist for the treatment of type II diabetes that received approval from the FDA [5,6]. This evidence concerns the gene GCG and type 2 diabetes mellitus.